输血相关急性肺损伤发病机制及防治措施研究进展  

Advances in the Pathogenesis,Prevention,and Treatment of Transfusion-related Acute Lung Injury

作　　者：胡嫒[1] 陈唯韫[1] 黄宇光[1] HU Ai;CHEN Weiyun;HUANG Yuguang(Department of Anesthesiology,PUMC Hospital,CAMS and PUMC,Beijing 100730,China)

机构地区：[1]中国医学科学院,北京协和医学院,北京协和医院麻醉科,北京100730

出　　处：《中国医学科学院学报》2020年第5期674-680,共7页Acta Academiae Medicinae Sinicae

基　　金：国家自然科学基金(81400049);中国医学科学院医学与健康科技创新工程项目(2016-I2M-3-024)。

摘　　要：输血相关急性肺损伤(TRALI)是输血导致的严重肺部并发症,已成为输血导致死亡的主要原因之一,其病理生理学机制尚未完全阐明,防治也面临巨大挑战。当前研究大多基于各种假说,探究多种效应细胞及效应分子在TRALI中的作用及可能存在的相关机制,本文总结了TRALI发病机制及防治措施的研究进展。Transfusion-related acute lung injury(TRALI)is a severe pulmonary complication of transfusion and has been one of the leading causes of transfusion-associated deaths.However,the pathogenesis of TRALI is still unclear,and treatment and prevention of this condition also face huge challenges.Many recent studies have explored the roles of various effector cells and effector molecules in TRALI and possible related mechanisms based on various hypotheses,in order to find the key factors that induce TRALI and the potential prevention measures.This article reviews the pathogenesis,prevention,and treatment of TRALI.

关 键 词：输血相关急性肺损伤 发病机制 预防措施 治疗措施 

分 类 号：R363.2+1[医药卫生—病理学]